pharmaphorum

FEBRUARY 14, 2022

Moderna is reportedly in late-stage negotiations with the UK government that could result in a new research and manufacturing facility being set up in the biotech ‘golden triangle’ between London, Oxford and Cambridge. The development has been prompted by a desire on the behalf of the US biotech to collaborate with the NHS, according to a report in the Financial Times, which cites people familiar with the matter.

Vaccines 105

Vaccines 105

Outsourcing Pharma

FEBRUARY 14, 2022

In this second of a two-part series, experts from the clinical research organization share thoughts on how data management technology, personnel, and partnerships have evolved.

59

59

pharmaphorum

FEBRUARY 14, 2022

A recent report has found that R&D productivity rose vertiginously during 2021, but how much of this was organic and how much can be attributed to the pandemic? In this feature, Ben Hargreaves looks at all of the factors involved and how the increased return can be maintained. The pharma industry has had a difficult time solving the issue of achieving greater productivity without significantly increasing the cost it takes to discover and commercialise new products.

Vaccines 96

Vaccines 96

Outsourcing Pharma

FEBRUARY 14, 2022

Cullinan Oncology has formed a strategic partnership with the Icahn School of Medicine at Mount Sinai to research and develop targeted therapies for cancer.

62

62

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

NICE

FEBRUARY 14, 2022

What is a NICE research recommendation? As NICE develops any of its guidance products, we identify gaps and uncertainties in the evidence base which could benefit from further research. The most important unanswered questions are developed into research recommendations. How do NICE & NIHR work together? NIHR have been screening NICE guidance for nearly 20 years to identify topics suitable for commissioning research.

52

52

Pharma Mirror

FEBRUARY 14, 2022

The concept of sustainability is gaining more traction in society with each passing day. Human activities pose numerous risks to the environment, so many industries and sectors are looking to become more sustainable. Can medical labs switch to greener practices without affecting the quality and accuracy of their output? The answer is a resounding yes.

52

52

Outsourcing Pharma

FEBRUARY 14, 2022

Darmstadt, Germany headquartered, Merck KGaA, is restructuring its life sciences business.

69

69

pharmaphorum

FEBRUARY 14, 2022

Seattle, US vaccine startup Curevo has raised $60 million in first-round financing that it says will be used to run head-to-head trials of its experimental shingles vaccines CRV-101 and GlaxoSmithKline’s market-leading Shingrix. The cash will fund a phase 2b trial in 678 people aged over 50 that will compare CRV?101’s immunogenicity and safety profile relative to Shingrix , according to Curevo.

Vaccines 52

Vaccines Immunization 52

Pharma Times

FEBRUARY 14, 2022

UK health secretary navigates the NHS roadmap as he plans to reform the UK’s healthcare ecosystem

44

44

pharmaphorum

FEBRUARY 14, 2022

Belgian biotech Oxurion has revealed new data from a phase 2 trial of its plasma kallikrein inhibitor THR-149, in development for people with diabetic macular oedema (DME) who don’t respond to standard therapy. New results from the first of two stages in the KALAHARI study of THR-149 showed that patients treated with the drug had a nine letter or more improvement on a standard best corrected visual acuity (BCVA) eye chart, which was maintained for at least four months after treatment with

FDA 64

FDA 64

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharma Times

FEBRUARY 14, 2022

Heart conditions among women in Wales are not being diagnosed due to systemic failures

39

39

pharmaphorum

FEBRUARY 14, 2022

Astellas and Seagen’s Padcev is on course to move further up the treatment pathway in bladder cancer, thanks to a positive readout in the EV-103 clinical trial. Padcev (enfortumab vedotin) is already approved as a second-line therapy for urothelial carcinoma (UC) after cisplatin chemotherapy and immunotherapy with checkpoint inhibitors, but Seagen and Astellas are working towards earlier use of the drug.

Chemotherapy 59

Chemotherapy FDA 59